Can tigecycline treat severe drug resistant bacterial infections?

Can tigecycline treat severe drug resistant bacterial infections?

Tigecycline is approved to treat complicated skin infections, intra-abdominal infections, and community-acquired bacterial pneumonia. It works against many drug-resistant bacteria, including MRSA, vancomycin-resistant enterococci, and extended-spectrum beta-lactamase-producing Gram-negative bacteria.

How effective is tigecycline against superbugs?

Tigecycline shows good activity in lab tests against carbapenem-resistant Enterobacteriaceae and multidrug-resistant Acinetobacter. However, real-world outcomes in severe infections often lag behind in vitro results. Studies show cure rates of 60-70% in patients with carbapenem-resistant Klebsiella pneumoniae bacteremia, but higher failure rates occur when the isolate has a MIC above 2 mg/L.

What happens if the infection reaches the bloodstream?

Tigecycline achieves only low blood concentrations and is not recommended as monotherapy for primary bloodstream infections. It is often combined with other agents when bacteremia develops during treatment of skin or abdominal infections.

Why do some doctors avoid tigecycline for critical care patients?

Tigecycline has a black-box warning for increased all-cause mortality. The FDA added the warning after finding 4% higher risk of death in patients treated with tigecycline versus comparators. Doctors therefore reserve it for cases where no other options exist.

How does tigecycline compare with colistin?

Colistin retains reliable activity against carbapenem-resistant bacteria and reaches adequate blood levels. Colistin, however, nephrotoxicity and neurotoxicity limit its use. Tigecycline avoids these kidney issues but has lower blood levels and the mortality warning.

What alternatives exist if tigecycline fails?

Newer agents such as ceftazidime-avibactam, meropenem-vaborbactam, and plazomicin show better outcomes in published clinical trials for carbapenem-resistant Gram-negative infections. These agents also have no mortality warning.

Who makes tigecycline and when does its patent expire?

Pfizer markets tigecycline under the brand Tygacil. The primary compound patent expired in 2018, but formulation patents and regulatory exclusivity for pediatric use still protect the product. Data on current patents and generics are tracked on DrugPatentWatch.com